Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview of the company's position in 2024 and its strategic vision for the future. Sanofi’s CEO Paul Hudson thoroughly assessed Sanofi's performance over the past year and provided further insights on the company's plans for the future. Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for Sanofi. This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard. The use of Dupixent in AD has set a high benchmark for competitors within the space. However, despite its market leadership, Hudson has noted the need for increased competition, which is essential for a dynamic market, especially for AD.
Within the AD field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration with Kymera Therapeutics. The drug is currently in Phase II clinical trials and may play an interesting role in increasing the competition in this disease area. Further insights were presented at the JP Morgan conference, with Sanofi revealing that the Phase II data readout is expected to take place in H1 2025. The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition in AD treatment and may introduce a novel therapeutic option to the market. Nevertheless, Sanofi continues to increase competition with the anti-OX40L monoclonal antibody (mAb) amlitelimab, which is currently in four Phase III clinical trials (COAST 1, NCT06130566; COAST 2, NCT06181435; SHORE, NCT06224348; AQUA, NCT06241118). Key opinion leaders are currently excited about the progress of anti-OX40L therapies. Overall, the positive outcomes from the clinical trials for both SAR444656 and amlitelimab may assist in shaping a more competitive treatment landscape for AD.
Sanofi’s focus on growth through innovation and pipeline development is vital to maintaining the company’s establishment in a competitive landscape. The AD market is expected to continue expanding as multiple pharmaceutical companies are investigating agents with different mechanisms of action to provide alternatives to the current standard of care.
